DescriptionSources: http://www.google.com/patents/WO1993000915A1?cl=enhttp://www.huntsman.com/performance_products/Media%20Library/a_MC348531CFA3EA9A2E040EBCD2B6B7B06/Products_MC348531D0B9FA9A2E040EBCD2B6B7B06/Amines_MC348531D0BECA9A2E040EBCD2B6B7B06/Ethyleneamines_MC348531D0CD3A9A2E040EBCD2B6B7B06/files/tetraethylenepentamine_tepa.pdfCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26581493 | http://pubs.acs.org/doi/abs/10.1021/ic50099a028?journalCode=inocaj | http://pubs.acs.org/doi/abs/10.1021/ic50048a017?journalCode=inocaj | https://clinicaltrials.gov/ct2/show/NCT01484470 | https://www.ncbi.nlm.nih.gov/pubmed/18209724 | https://www.ncbi.nlm.nih.gov/pubmed/16219531
Sources: http://www.google.com/patents/WO1993000915A1?cl=enhttp://www.huntsman.com/performance_products/Media%20Library/a_MC348531CFA3EA9A2E040EBCD2B6B7B06/Products_MC348531D0B9FA9A2E040EBCD2B6B7B06/Amines_MC348531D0BECA9A2E040EBCD2B6B7B06/Ethyleneamines_MC348531D0CD3A9A2E040EBCD2B6B7B06/files/tetraethylenepentamine_tepa.pdf
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26581493 | http://pubs.acs.org/doi/abs/10.1021/ic50099a028?journalCode=inocaj | http://pubs.acs.org/doi/abs/10.1021/ic50048a017?journalCode=inocaj | https://clinicaltrials.gov/ct2/show/NCT01484470 | https://www.ncbi.nlm.nih.gov/pubmed/18209724 | https://www.ncbi.nlm.nih.gov/pubmed/16219531
Tetraethylenepentamine (TEPA) is a low-molecular-weight linear polyamine exerting metal-chelating properties. TEPA is widely used in industrial applications. The principal hazards that arise in working with TEPA are those associated with similar organic amines; namely, a corrosive action on skin and eyes. TEPA biological activity was attributed to its effect on cellular Cu levels as (a) treatment with TEPA resulted in reduction of cellular Cu, and (b) excess of Cu reversed TEPA's activity and accelerated differentiation. TEPA was shown to attenuate the differentiation of ex vivo cultured hematopoietic cells resulting in preferential expansion of early progenitors. A phase I/II trial was performed to test the feasibility and safety of transplantation of CD133+ cord blood (CB) hematopoietic progenitors cultured in media containing stem cell factor, FLT-3 ligand, interleukin-6, thrombopoietin and TEPA. Transplanting a population of CD133+ CB cells which were expanded ex vivo for 21 days using SCF, FLT3, IL-6, TPO and the copper chelator TEPA (StemEx) was feasible. The expanded cells were well tolerated, with no infusion-related adverse events observed.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18047399 |
|||
Target ID: CHEMBL2363057 |
|||
Target ID: CHEMBL2364175 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | StemEx Approved UseUnknown |
|||
Palliative | COLESTID Approved UseCOLESTID Granules and FLAVORED COLESTID Granules are indicated as adjunctive therapy to diet for the reduction of elevated serum total and low-density lipoprotein (LDL) cholesterol in patients with primary hypercholesterolemia (elevated low density lipoproteins [LDL] cholesterol) who do not respond adequately to diet. Generally, COLESTID and FLAVORED COLESTID have no clinically significant effect on serum
triglycerides, but with its use triglyceride levels may be raised in some patients. Launch Date2.28959994E11 |
Substance Class |
Polymer
Created
by
admin
on
Edited
Sat Dec 16 13:14:41 UTC 2023
by
admin
on
Sat Dec 16 13:14:41 UTC 2023
|
Record UNII |
K50N755924
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
NBK548432
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
||
|
NDF-RT |
N0000175365
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
||
|
WHO-ATC |
C10AC02
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
||
|
NCI_THESAURUS |
C98148
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
||
|
NDF-RT |
N0000180292
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
K50N755924
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | |||
|
m3729
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | Merck Index | ||
|
D003084
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | |||
|
62816
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | |||
|
2738
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | |||
|
26658-42-4
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | |||
|
2685
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | RxNorm | ||
|
Colestipol
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | |||
|
COLESTIPOL
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | |||
|
C81540
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | |||
|
728
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | |||
|
3814
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | |||
|
DB00375
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | |||
|
K50N755924
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | |||
|
SUB01425MIG
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | |||
|
147003
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | |||
|
DTXSID901009549
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY | |||
|
100000087961
Created by
admin on Sat Dec 16 13:14:41 UTC 2023 , Edited by admin on Sat Dec 16 13:14:41 UTC 2023
|
PRIMARY |